Poster-Quality of Life and Outcomes
October 25, 2021
Characterizing Activities of Daily Living in MS Patients with Processing Speed Scores Above and below a Threshold Previously Shown to Predict Employment Status
Background: Cognitive impairment can occur early in the course of multiple sclerosis (MS) and worsen progressively over time, impacting...
Poster-Disease-modifying Therapy
October 25, 2021
COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths
Background: Emerging data from people with multiple sclerosis (PwMS) suggest that some disease-modifying therapies (DMTs) may impact the...
Poster-Disease-modifying Therapy
October 25, 2021
Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data
Background: The majority of real-world data (RWD) on disease-modifying treatments (DMTs) for multiple sclerosis (MS) is based on clinical...
Platform-Disease Modifying Therapies
October 25, 2021
COVID-19 Vaccine Response in People with MS Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy
Background: COVID-19 is a potentially fatal respiratory illness, caused by the novel coronavirus, SARS-CoV-2, which developed into the...